New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and screening.

Cancer diagnoses traditionally require invasive or labor-intensive procedures such as tissue biopsies. Researchers at the Ludwig-Maximilians-Universität München (LMU) have now reported on a method ...

PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects Prostate Cancer," (1) demonstrating clinical validation ...

Final random-forest-based models outperformed all publicly available risk scores on internal and external test sets.

A breakthrough in microbiome research could change how colorectal cancer is detected—no colonoscopy required. Scientists used AI to map gut bacteria at an unprecedented level of detail, revealing ...

Head and neck cancers represent a biologically heterogeneous group of malignancies requiring accurate diagnosis, staging, and risk stratification for ...

The Gyne Cancer Company™ — today announced the publication of peer-reviewed evidence demonstrating that molecular signals ...

Partnership expands access to breakthrough blood-based cancer screening into Superpower's comprehensive health check and personalized plans. SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, ...

MethylScan is a low-cost blood test that detects multiple cancers and liver diseases by analyzing DNA methylation patterns ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.